High Blood Pressure & Cardiovascular Prevention最新文献

筛选
英文 中文
Cardiovascular Risk Factors and Diseases and Awareness of Related Burden in Women: Results of a Survey in Italian Pharmacies.
IF 3.1
High Blood Pressure & Cardiovascular Prevention Pub Date : 2025-03-01 Epub Date: 2025-02-06 DOI: 10.1007/s40292-025-00701-4
Rita Del Pinto, Maria Vitale, Maria Eugenia Morreale, Clara Mottinelli, Maria Lorenza Muiesan, Massimo Volpe, Claudio Ferri
{"title":"Cardiovascular Risk Factors and Diseases and Awareness of Related Burden in Women: Results of a Survey in Italian Pharmacies.","authors":"Rita Del Pinto, Maria Vitale, Maria Eugenia Morreale, Clara Mottinelli, Maria Lorenza Muiesan, Massimo Volpe, Claudio Ferri","doi":"10.1007/s40292-025-00701-4","DOIUrl":"10.1007/s40292-025-00701-4","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiovascular diseases (CVD) represent the leading cause of morbidity and mortality for women worldwide, yet they are often unaware of this heavy burden.</p><p><strong>Aim: </strong>To assess cardiovascular risk awareness among Italian women.</p><p><strong>Methods: </strong>Following World Heart Day 2023, a cardiovascular prevention campaign was conducted in Italian pharmacies to evaluate the effectiveness of screening activities offered by pharmacies and raise awareness of cardiovascular health status among Italian women. Cardiovascular risk profile and perception of CVD burden relative to other common female-specific diseases were assessed. Blood pressure (BP) measurement and ECG recording were performed.</p><p><strong>Results: </strong>A total of 1510 women (84.7% < 70 years), enrolled at 91 pharmacies, were included. The most prevalent cardiovascular risk factor was sedentary lifestyle (57.9%), followed by overweight/obesity (44.3%), hypercholesterolemia (37.9%), hypertension (31.3%), family history of early CVD (28.7%), smoking (20.6%), and diabetes (5%). CVD and/or kidney disease were uncommon (3.6%), but 1 in 4 women was classified as being at increased cardiovascular risk, and 47.5% had some type of ECG abnormalities, requiring further assessments in 18% cases. Less than 1 in 3 women was aware of the burden represented by CVD, being the majority mostly concerned with breast cancer and osteoporosis as potential health threats.</p><p><strong>Conclusions: </strong>The burden of cardiovascular risk factors is high, and the perception of related health threat is low among the examined sample of Italian women, supporting the urgent need to raise awareness of CVD in women as a major health issue and to undertake effective, tailored preventive strategies to reduce such risk in a timely fashion.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"191-198"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influence of Persistently Elevated LDL Values on Carotid Intima Media Thickness in Elite Athletes. LDL持续升高对优秀运动员颈动脉内膜中膜厚度的影响
IF 3.1
High Blood Pressure & Cardiovascular Prevention Pub Date : 2025-03-01 Epub Date: 2025-01-08 DOI: 10.1007/s40292-024-00698-2
Giuseppe Di Gioia, Lorenzo Buzzelli, Armando Ferrera, Viviana Maestrini, Maria Rosaria Squeo, Erika Lemme, Sara Monosilio, Andrea Serdoz, Antonio Pelliccia
{"title":"Influence of Persistently Elevated LDL Values on Carotid Intima Media Thickness in Elite Athletes.","authors":"Giuseppe Di Gioia, Lorenzo Buzzelli, Armando Ferrera, Viviana Maestrini, Maria Rosaria Squeo, Erika Lemme, Sara Monosilio, Andrea Serdoz, Antonio Pelliccia","doi":"10.1007/s40292-024-00698-2","DOIUrl":"10.1007/s40292-024-00698-2","url":null,"abstract":"<p><strong>Introduction: </strong>Carotid IMT is a recognized marker for early atherosclerotic changes and a predictor of future CV events. Previous studies showed 11% increased risk of myocardial infarction with each 0.1 mm incremental increase of carotid IMT. In general population, LDL cholesterol levels are positively correlated with carotid IMT in both cross-sectional and longitudinal studies while its role in elite athletes remains understudied.</p><p><strong>Aim: </strong>This study aimed to investigate the correlation between persistent lipid profile alterations and early markers of atherosclerosis, specifically carotid IMT, in a cohort of elite athletes.</p><p><strong>Methods: </strong>We included 302 athletes serially evaluated for a prolonged time period. Anthropometric data, blood tests for lipid profiles, and carotid IMT measurements were collected. Dyslipidemia was defined as LDL ≥ 116 mg/dL, and persistent elevation when LDL values remained above the threshold limits in at least three pre-participation screenings. Categorical variables were expressed as frequencies and percentages and were compared using Fisher's exact test or Chi-square test, as appropriate.</p><p><strong>Results: </strong>91 athletes (30.1%) had persistently elevated LDL levels. Dyslipidemic athletes were older (30.7 ± 5.7 vs. 29.1 ± 4.1 years, p = 0.008), had higher BMI (p = 0.032), and a higher prevalence of obesity (5.5% vs. 0.5%, p = 0.004) compared to those with normal lipid profiles. Additionally, they had higher total cholesterol (p < 0.0001) and triglycerides (p < 0.0001) but similar HDL levels (p = 0.213). Globally, athletes with altered LDL profiles over long-time period showed higher IMT (0.60 ± 0.10 mm vs. 0.57 ± 0.07 mm, p = 0.014). In particular, longer exposure to elevated LDL was significantly associated with increased IMT (0.61 ± 0.12 mm vs. 0.57 ± 0.06 mm, p = 0.035).</p><p><strong>Conclusions: </strong>Our study highlights the association between persistently elevated LDL-C and increased carotid IMT in elite athletes, with longer exposure time correlating with more pronounced carotid changes. These findings underscore the importance of regular monitoring of blood lipid profiles and carotid IMT measurements as a non-invasive, cost-effective method to prevent atherosclerotic vascular disease.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"171-179"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reducing LDL-Cholesterol to Very Low Levels: Sailing Between Established Benefits and Potential Risks.
IF 3.1
High Blood Pressure & Cardiovascular Prevention Pub Date : 2025-03-01 Epub Date: 2025-02-25 DOI: 10.1007/s40292-025-00708-x
Stefania Angela Di Fusco, Massimo Volpe, Federico Nardi, Andrea Matteucci, Stefano Aquilani, Gaetano Marino, Alessandro Aiello, Furio Colivicchi
{"title":"Reducing LDL-Cholesterol to Very Low Levels: Sailing Between Established Benefits and Potential Risks.","authors":"Stefania Angela Di Fusco, Massimo Volpe, Federico Nardi, Andrea Matteucci, Stefano Aquilani, Gaetano Marino, Alessandro Aiello, Furio Colivicchi","doi":"10.1007/s40292-025-00708-x","DOIUrl":"10.1007/s40292-025-00708-x","url":null,"abstract":"<p><p>In view of the growing evidence supporting more marked reductions of low-density lipoprotein cholesterol (LDL-C), according to the concept of \"the lower is better\" and with the availability of powerful and well tolerated lipid-lowering drugs, physicians are facing today with the clinical management of patients with very low LDL-C levels. The fear of potential risks linked to extreme reductions of LDL-C down to very low levels may lead to the de-escalation of treatments with consequent paradoxical unfavorable consequences due to the exposure to a higher cardiovascular risk. The aim of this review is to point out evidence of very low LDL-C clinical impact, with a focus on potential adverse effects. Research on cholesterol homeostasis has identified complex mechanisms which guarantee cell functions even when circulating cholesterol levels are very low. The almost complete self-sufficiency of the human body in terms of cholesterol needs is confirmed by evidence derived from genetically determined models with very low LDL-C levels. Studies on the potential harm of lowering LDL-C to very low concentrations do not confirm an increased risk of cancer or neurodegenerative disease attributable to lipid-lowering treatments, whereas evidence suggests a potential benefit in these settings. A potential increased risk of hemorrhagic stroke has been reported, suggesting tight monitoring and control of blood pressure should be implemented in patients with very low LDL-C levels. With regard to statin treatment, a dose-dependent increased risk of newly diagnosed diabetes has been reported. This adverse effect has not been found with more recently approved lipid-lowering drugs.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"139-149"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Relationship Between Blood Pressure and Heart Rate Response During Exercise Testing with Microcirculation Indices. 微循环指标运动试验中血压与心率反应的关系。
IF 3.1
High Blood Pressure & Cardiovascular Prevention Pub Date : 2025-03-01 Epub Date: 2024-12-24 DOI: 10.1007/s40292-024-00695-5
Ioannis Liatakis, Kyriakos Dimitriadis, Eleni Manta, Ioannis Andrikou, Nikolaos Pyrpyris, Fotios Tatakis, Dimitrios Konstantinidis, Konstantinos Thomopoulos, Antonios Manolis, Dimitrios Tousoulis, Konstantinos Tsioufis
{"title":"The Relationship Between Blood Pressure and Heart Rate Response During Exercise Testing with Microcirculation Indices.","authors":"Ioannis Liatakis, Kyriakos Dimitriadis, Eleni Manta, Ioannis Andrikou, Nikolaos Pyrpyris, Fotios Tatakis, Dimitrios Konstantinidis, Konstantinos Thomopoulos, Antonios Manolis, Dimitrios Tousoulis, Konstantinos Tsioufis","doi":"10.1007/s40292-024-00695-5","DOIUrl":"10.1007/s40292-024-00695-5","url":null,"abstract":"<p><strong>Introduction: </strong>Hypertension is associated with changes in microcirculation, while increased blood pressure (BP) during exercise stress testing has been correlated with adverse outcomes.</p><p><strong>Aim: </strong>To evaluate the relationship of microcirculation with exercise BP response in hypertensive individuals.</p><p><strong>Methods: </strong>105 hypertensive individuals underwent exercise stress testing and nail-fold videocapillaroscopy assessment, in order to evaluate the relationship of BP response to exercise with capillary density.</p><p><strong>Results: </strong>A significant negative correlation between diastolic BP at 1-minute recovery and capillary density was revealed (Pearson's r = -0.365, p = 0.043). A significant negative correlation was also observed between capillary density and peak heart rate (HR) (Pearson's r = -0.364, p = 0.024) and HR increase from stage 1 to 2 (Pearson's r = -0.746, p = 0.013).</p><p><strong>Conclusion: </strong>Capillary rarefaction is associated with an abnormal BP and HR response to exercise, highlighting the role of microcirculation in BP regulation during exercise.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"217-222"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Efficacy of Continuous Positive Airway Pressure and Antihypertensive Medications in Obstructive Sleep Apnea-Related Hypertension: A Narrative Review. 持续气道正压和降压药物治疗阻塞性睡眠呼吸暂停相关高血压的比较疗效:一项叙述性综述。
IF 3.1
High Blood Pressure & Cardiovascular Prevention Pub Date : 2025-03-01 Epub Date: 2024-12-24 DOI: 10.1007/s40292-024-00691-9
Olumide Damilola Akinmoju, Gbolahan Olatunji, Emmanuel Kokori, Ikponmwosa Jude Ogieuhi, Adetola Emmanuel Babalola, Emeka Stanley Obi, Chidera Stanley Anthony, Odemona Glory Toluwanibukun, Adewunmi Akingbola, Adedoyin Esther Alao, Adenowo Goodness Boluwatife, Aarushi Venkatraman, Areesha Babar, Nicholas Aderinto
{"title":"Comparative Efficacy of Continuous Positive Airway Pressure and Antihypertensive Medications in Obstructive Sleep Apnea-Related Hypertension: A Narrative Review.","authors":"Olumide Damilola Akinmoju, Gbolahan Olatunji, Emmanuel Kokori, Ikponmwosa Jude Ogieuhi, Adetola Emmanuel Babalola, Emeka Stanley Obi, Chidera Stanley Anthony, Odemona Glory Toluwanibukun, Adewunmi Akingbola, Adedoyin Esther Alao, Adenowo Goodness Boluwatife, Aarushi Venkatraman, Areesha Babar, Nicholas Aderinto","doi":"10.1007/s40292-024-00691-9","DOIUrl":"10.1007/s40292-024-00691-9","url":null,"abstract":"<p><strong>Introduction: </strong>Obstructive sleep apnea (OSA) presents a significant global health concern, affecting a substantial portion of the population, particularly among young and middle-aged adults.</p><p><strong>Aim: </strong>This review aims to assess the efficacy of continuous positive airway pressure (CPAP) compared to antihypertensive medications in managing OSA-related hypertension.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted across multiple databases, yielding studies published from 2000 to March 2024 that investigated CPAP, antihypertensives, or their combination therapy in OSA patients. Six definitive studies were analyzed, including two randomized controlled trials (RCTs), one randomized double-blind placebo-controlled crossover trial, one placebo-controlled trial, one open-label multicenter trial, and one longitudinal cohort study. These studies comprised 939 participants, with intervention durations ranging from four weeks to six months.</p><p><strong>Results: </strong>Analysis of CPAP monotherapy revealed variable efficacy, with some studies demonstrating significant reductions in 24-hour mean blood pressure and diastolic pressure, while others reported non-significant changes. CPAP therapy combined with antihypertensives showed additive effects, particularly in reducing office blood pressure measurements. Antihypertensive medications, such as valsartan, exhibited superior efficacy in reducing blood pressure compared to CPAP alone. Factors influencing therapy effectiveness included CPAP compliance, patient characteristics, and coexisting comorbidities. Patients with good CPAP adherence experienced greater reductions in blood pressure. The duration of exposure to OSA and the type of hypertension also impacted the therapy response.</p><p><strong>Conclusion: </strong>While CPAP and antihypertensive medications offer significant benefits in managing hypertension among OSA patients, challenges such as CPAP intolerance and medication side effects exist. Personalized treatment considering individual patient factors is crucial for optimal management.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"127-137"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy.
IF 3.1
High Blood Pressure & Cardiovascular Prevention Pub Date : 2025-03-01 Epub Date: 2025-02-19 DOI: 10.1007/s40292-025-00705-0
Arturo Cesaro, Vincenzo Acerbo, Francesco Scialla, Enrica Golia, Claudia Concilio, Gianmaria Scherillo, Gianantonio De Michele, Vincenzo de Sio, Antonio Capolongo, Luisa Di Donato, Maria Grazia Monaco, Simona Sperlongano, Alberto Ruggiero, Felice Gragnano, Elisabetta Moscarella, Carmine Riccio, Paolo Calabrò
{"title":"Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy.","authors":"Arturo Cesaro, Vincenzo Acerbo, Francesco Scialla, Enrica Golia, Claudia Concilio, Gianmaria Scherillo, Gianantonio De Michele, Vincenzo de Sio, Antonio Capolongo, Luisa Di Donato, Maria Grazia Monaco, Simona Sperlongano, Alberto Ruggiero, Felice Gragnano, Elisabetta Moscarella, Carmine Riccio, Paolo Calabrò","doi":"10.1007/s40292-025-00705-0","DOIUrl":"10.1007/s40292-025-00705-0","url":null,"abstract":"<p><strong>Introduction: </strong>Accurate risk assessment is critical in cardiovascular (CV) prevention, yet physicians often underestimate CV risk, leading to inadequate preventive measures.</p><p><strong>Aim: </strong>This study evaluates the concordance between physician-perceived CV risk and calculated CV risk in a primary prevention setting.</p><p><strong>Methods: </strong>This cross-sectional study included primary prevention patients from the Cardiology Outpatient Clinic of Caserta Hospital, Italy. Two independent cardiologists evaluated the physician-perceived risk, and a third resolved discrepancies. CV risk was calculated using SCORE2 for patients with 70 years or less and SCORE2-OP for those with more than 70 years. The concordance between perceived and calculated risks was assessed using Cohen's kappa coefficient. Multivariate logistic regression analysis was performed to examine the influence of risk estimation on achieving low-density lipoprotein cholesterol (LDL-C) targets recommended by the ESC.</p><p><strong>Results: </strong>389 patients had complete data for CV risk calculation. Physician-perceived risk categorized 8.7% of patients as low/moderate, 37.8% as high, and 53.5% as very-high risk. In contrast, calculated CV risk according to the SCORE2/SCORE2-OP classified 8% as low/moderate, 5.7% as high, and 86.4% as very-high risk. The concordance between perceived and calculated CV risk was poor (Cohen's kappa 0.208, p < 0.001). Underestimated patients reached LDL-C targets in 16% of cases, well-estimated in 34.5%, and overestimated in 76.9%. Statin use was significantly lower in patients with underestimated CV risk (29.2%) compared to well-estimated (50%) and overestimated (76.9%) groups (p < 0.001). Multivariate analysis showed that patients with overestimated risk were more likely to achieve LDL-C targets (OR 5.33, CI 1.33-21.42, p = 0.018), whereas underestimated patients were 47% less likely (OR 0.53, CI 0.3-0.93, p = 0.027).</p><p><strong>Conclusions: </strong>A significant discrepancy exists between physician-perceived and calculated CV risk, leading to risk underestimation in over one-third of patients. This underestimation is associated with lower LDL-C target achievement and reduced statin use.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"199-208"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of nebivolol monotherapy or combination therapy on blood pressure levels in patients with hypertension: an updated systematic review and multilevel meta-analysis of 91 randomized controlled trials. 奈必洛尔单药或联合疗法对高血压患者血压水平的影响:91 项随机对照试验的最新系统综述和多层次荟萃分析。
IF 3.1
High Blood Pressure & Cardiovascular Prevention Pub Date : 2025-01-01 Epub Date: 2024-10-29 DOI: 10.1007/s40292-024-00687-5
Athanasios Manolis, Paschalis Karakasis, Dimitrios Patoulias, Michalis Doumas, Manolis Kallistratos, Costas Thomopoulos, Maria Koutsaki, Guido Grassi, Giuseppe Mancia
{"title":"Effect of nebivolol monotherapy or combination therapy on blood pressure levels in patients with hypertension: an updated systematic review and multilevel meta-analysis of 91 randomized controlled trials.","authors":"Athanasios Manolis, Paschalis Karakasis, Dimitrios Patoulias, Michalis Doumas, Manolis Kallistratos, Costas Thomopoulos, Maria Koutsaki, Guido Grassi, Giuseppe Mancia","doi":"10.1007/s40292-024-00687-5","DOIUrl":"10.1007/s40292-024-00687-5","url":null,"abstract":"<p><strong>Aims: </strong>To systematically appraise and summarize the available evidence from published randomized controlled trials considering the effect of nebivolol on blood pressure in patients with hypertension.</p><p><strong>Methods: </strong>Literature search was performed through Medline (via PubMed), Cochrane Library and Scopus until December 15, 2023. Double-independent study selection, data extraction and quality assessment were performed. Evidence was pooled with three-level mixed-effects meta-analysis.</p><p><strong>Results: </strong>In total, 7,737 participants with hypertension, who were treated with nebivolol, were analyzed across 91 RCTs. Nebivolol was associated with significantly greater reduction in office systolic and diastolic BP compared to placebo (MD = - 6.01 mmHg; 95% CI = [- 7.46, - 4.55] and MD = - 5.01 mmHg; 95% CI = [- 5.91, - 4.11], respectively). Moreover, resulted a similar reduction in systolic BP (MD = - 0.22 mmHg; 95% CI = [- 0.91, 0.46]) and a significantly greater reduction in diastolic BP compared to the active comparator (MD = - 0.71 mmHg; 95% CI = [- 1.27, - 0.16]). When considering the effect of nebivolol on 24-hour ambulatory BP, notable reductions were observed compared to placebo. In contrast, compared to the active comparators, there was no significant difference in systolic BP reduction, but a significant reduction in diastolic BP favoring nebivolol. Based on moderator analyses, the impact of nebivolol on the pooled estimates remained independent of the dose of nebivolol, age, male sex, trial duration, body mass index (BMI), baseline diabetes, heart failure, and baseline systolic and diastolic BP.</p><p><strong>Conclusion: </strong>Nebivolol, compared to placebo, showed a significant BP reduction and was non-inferior to other active comparators in terms of BP reduction.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"7-31"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Triple Therapy with Telmisartan, Amlodipine, and Rosuvastatin (TAR) Versus Telmisartan/Amlodipine (TA) and Telmisartan/Rosuvastatin (TR) Combinations in Hypertension and Dyslipidemia: A Systematic Review and Meta-analysis. 特米沙坦、氨氯地平和瑞舒伐他汀三联疗法(TAR)与特米沙坦/氨氯地平(TA)和特米沙坦/瑞舒伐他汀组合(TR)治疗高血压和血脂异常:系统综述与元分析》。
IF 3.1
High Blood Pressure & Cardiovascular Prevention Pub Date : 2025-01-01 Epub Date: 2024-11-19 DOI: 10.1007/s40292-024-00689-3
Shady Habboush, Navyamani V Kagita, Ahmed F Gadelmawla, Ahmed Elmoursi, Nooraldin Merza, Ahmed A Abdo, Al Hussein M Zahran, Moustafa Eldeib, Alsayed A Almarghany, Mohamed M Abdelfadil, Mohamed A Abdelkarim, Islam Shawky, Omar M Mohammed, Abdullah Alharran, Mahmoud M Ali, Shereef Elbardisy
{"title":"Triple Therapy with Telmisartan, Amlodipine, and Rosuvastatin (TAR) Versus Telmisartan/Amlodipine (TA) and Telmisartan/Rosuvastatin (TR) Combinations in Hypertension and Dyslipidemia: A Systematic Review and Meta-analysis.","authors":"Shady Habboush, Navyamani V Kagita, Ahmed F Gadelmawla, Ahmed Elmoursi, Nooraldin Merza, Ahmed A Abdo, Al Hussein M Zahran, Moustafa Eldeib, Alsayed A Almarghany, Mohamed M Abdelfadil, Mohamed A Abdelkarim, Islam Shawky, Omar M Mohammed, Abdullah Alharran, Mahmoud M Ali, Shereef Elbardisy","doi":"10.1007/s40292-024-00689-3","DOIUrl":"10.1007/s40292-024-00689-3","url":null,"abstract":"<p><strong>Introduction: </strong>Hypertension and dyslipidemia are common contributors to cardiovascular disease (CVD), often occurring together. Effectively Managing both is key to reducing mortality and morbidity, but complex regimens reduce adherence.</p><p><strong>Aim: </strong>This study investigated the comparative efficacy and safety of a three-drug regimen (TAR) containing telmisartan, amlodipine, and rosuvastatin against two-drug combinations (TA and TR) for managing hypertension and dyslipidemia.</p><p><strong>Methods: </strong>We searched PubMed, Web of Science, Cochrane, Embase, and Scopus databases for relevant articles matching our inclusion criteria. Following the application of inclusion criteria, four studies were selected for qualitative analysis and four studies for meta-analysis.</p><p><strong>Results: </strong>Our analysis showed TAR [n = 155] significantly reduced mean systolic blood pressure (MSSBP) at week 4 compared to TR (n = 163) (MD = -15.65 mmHg) and TA (MD = -4.63 mmHg). TAR also showed superiority over all groups (TR [n = 163], TA [n = 162]) in MSSBP reduction. For low-density lipoprotein-cholesterol (LDL-C), TAR only showed a significant difference at week 4 compared to TA (MD = -86.41 mg/dL), with no difference between TAR and TR at either week 4 or 8.</p><p><strong>Conclusion: </strong>Our findings suggest that TAR may be a safe and effective therapeutic option for the concurrent management of hypertension and dyslipidemia. However, there is no significant difference regarding adverse events between both arms.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"49-60"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Calling for Action: The Need of Large-Scale Cohorts to Uncover the Cardiovascular Risk in Non-Sleepy Obstructive Sleep Apnea. 呼吁行动起来:需要大规模队列研究来揭示非睡眠型阻塞性睡眠呼吸暂停症的心血管风险。
IF 3.1
High Blood Pressure & Cardiovascular Prevention Pub Date : 2025-01-01 Epub Date: 2024-10-12 DOI: 10.1007/s40292-024-00680-y
Giuseppe Maiolino, Miguel Angel Martinez Garcia, Davide Soranna, Antonella Zambon, Roberto Vettor, Gianfranco Parati, David Gozal, Martino F Pengo
{"title":"Calling for Action: The Need of Large-Scale Cohorts to Uncover the Cardiovascular Risk in Non-Sleepy Obstructive Sleep Apnea.","authors":"Giuseppe Maiolino, Miguel Angel Martinez Garcia, Davide Soranna, Antonella Zambon, Roberto Vettor, Gianfranco Parati, David Gozal, Martino F Pengo","doi":"10.1007/s40292-024-00680-y","DOIUrl":"10.1007/s40292-024-00680-y","url":null,"abstract":"<p><p>Since randomized clinical trials currently do not support continuous positive airway pressure treatment of asymptomatic obstructive sleep apnea (OSA) we proposed the Obesity, Symptoms, and CARdiovascular assessment (OSCAR) algorithm to aid clinicians in the management of asymptomatic low-risk moderate-severe OSA, focusing on weight loss, symptoms and cardiovascular disease (CVD) risk assessment. Exploiting the data of the Sleep Heart Health Study we selected subjects with a body mass index (BMI) < 30 Kg/m<sup>2</sup>, no history of CVD or sleepiness and compared 552 patients with moderate-severe OSA (OSCAR(-)) to 916 individuals without OSA (No-OSA). After adjusting for age, gender, and BMI, there was no significant difference in the risk of major adverse cardiovascular events (MACE) between OSCAR(-) and No-OSA (1.05; 95%CI 0.81-1.37). The study suggests that low-risk moderate-severe OSA patients may not have a greater risk of MACE compared to those without OSA and highlights the need for further research on this topic.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"121-123"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypertension in the Shadows of Conflict: The Impact of the Sudan War on Blood Pressure Management. 冲突阴影下的高血压:苏丹战争对血压管理的影响。
IF 3.1
High Blood Pressure & Cardiovascular Prevention Pub Date : 2025-01-01 Epub Date: 2024-10-24 DOI: 10.1007/s40292-024-00684-8
Ibrahim Nagmeldin Hassan, Nagmeldin Abuassa, Mohamed Ibrahim
{"title":"Hypertension in the Shadows of Conflict: The Impact of the Sudan War on Blood Pressure Management.","authors":"Ibrahim Nagmeldin Hassan, Nagmeldin Abuassa, Mohamed Ibrahim","doi":"10.1007/s40292-024-00684-8","DOIUrl":"10.1007/s40292-024-00684-8","url":null,"abstract":"<p><p>The Sudan conflict has severely impacted hypertension management, exacerbating the condition through chronic stress, disrupted healthcare, and lifestyle changes. Hypertension, a major risk factor for cardiovascular diseases, worsens with war-related stress and limited access to medications due to damaged healthcare infrastructure. Additionally, displacement, economic hardship, and food insecurity contribute to poor diets and reduced physical activity, further complicating blood pressure control. This article highlights the urgent need for adaptive healthcare strategies, such as mobile clinics and international aid, to address these challenges. A concerted effort is required to improve hypertension management and outcomes in conflict-affected populations.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"125-126"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信